Literature DB >> 22183689

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.

Romina Lomonaco1, Carolina Ortiz-Lopez, Beverly Orsak, Amy Webb, Jean Hardies, Celia Darland, Joan Finch, Amalia Gastaldelli, Stephen Harrison, Fermin Tio, Kenneth Cusi.   

Abstract

UNLABELLED: The role of adipose tissue insulin resistance in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) remains unclear. To evaluate this, we measured in 207 patients with NAFLD (age = 51 ± 1, body mass index = 34.1 ± 0.3 kg/m(2) ) and 22 controls without NAFLD (no NAFLD) adipose tissue insulin resistance by means of a validated index (Adipo-IR(i) = plasma free fatty acids [FFA] x insulin [FPI] concentration) and as the suppression of plasma FFA during an oral glucose tolerance test and by a low-dose insulin infusion. We also explored the relationship between adipose tissue insulin resistance with metabolic and histological parameters by dividing them based on quartiles of adipose tissue insulin resistance (Adipo-IR(i) quartiles: Q1 = more sensitive; Q4 = more insulin resistant). Hepatic insulin resistance, measured as an index derived from endogenous glucose production x FPI (HIRi), and muscle insulin sensitivity, were assessed during a euglycemic insulin clamp with 3-[(3) H] glucose. Liver fat was measured by magnetic resonance imaging and spectroscopy, and a liver biopsy was performed to assess liver histology. Compared to patients without steatosis, patients with NAFLD were insulin resistant at the level of adipose tissue, liver, and skeletal muscle and had higher plasma aspartate aminotransferase and alanine aminotransferase, triglycerides, and lower high-density lipoprotein cholesterol and adiponectin levels (all P < 0.01). Metabolic parameters, hepatic insulin resistance, and liver fibrosis (but not necroinflammation) deteriorated as quartiles of adipose tissue insulin resistance worsened (all P < 0.01).
CONCLUSION: Adipose tissue insulin resistance plays a key role in the development of metabolic and histological abnormalities of obese patients with NAFLD. Treatment strategies targeting adipose tissue insulin resistance (e.g., weight loss and thiazolidinediones) may be of value in this population.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22183689     DOI: 10.1002/hep.25539

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  122 in total

1.  Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.

Authors:  Lauren N Bell; Jiangxia Wang; Sriya Muralidharan; Sadhana Chalasani; Allison M Fullenkamp; Laura A Wilson; Arun J Sanyal; Kris V Kowdley; Brent A Neuschwander-Tetri; Elizabeth M Brunt; Arthur J McCullough; Nathan M Bass; Anna Mae Diehl; Aynur Unalp-Arida; Naga Chalasani
Journal:  Hepatology       Date:  2012-08-21       Impact factor: 17.425

Review 2.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.

Authors:  Chiara Saponaro; Melania Gaggini; Amalia Gastaldelli
Journal:  Curr Diab Rep       Date:  2015-06       Impact factor: 4.810

4.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

5.  Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study.

Authors:  Nadia Pallotta; Tiziana Filardi; Anna Carnovale; Luciano Nieddu; Paola Mariani; Giuseppina Vincoli; Andrea Lenzi; Susanna Morano
Journal:  Endocrine       Date:  2016-07-15       Impact factor: 3.633

6.  Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β-Cell) Function.

Authors:  Mohammad S Siddiqui; Kai L Cheang; Velimir A Luketic; Sherry Boyett; Michael O Idowu; Kavish Patidar; Puneet Puri; Scott Matherly; Richard T Stravitz; Richard K Sterling; Arun J Sanyal
Journal:  Dig Dis Sci       Date:  2015-03-18       Impact factor: 3.199

7.  Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.

Authors:  Rohit Loomba; Oswald Quehenberger; Aaron Armando; Edward A Dennis
Journal:  J Lipid Res       Date:  2014-11-17       Impact factor: 5.922

Review 8.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 9.  Mechanisms of adverse cardiometabolic consequences of obesity.

Authors:  Carlos M Diaz-Melean; Virend K Somers; Juan Pablo Rodriguez-Escudero; Prachi Singh; Ondrej Sochor; Ernesto Manuel Llano; Francisco Lopez-Jimenez
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

10.  Peripheral adipose tissue insulin resistance alters lipid composition and function of hippocampal synapses.

Authors:  Hanaa S Sallam; Batbayar Tumurbaatar; Wen-Ru Zhang; Demidmaa Tuvdendorj; Manisha Chandalia; Filippo Tempia; Fernanda Laezza; Giulio Taglialatela; Nicola Abate
Journal:  J Neurochem       Date:  2015-02-26       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.